DOCSLIB.ORG

Index to USP 39–NF 34 the Following Index Is for Convenience and Informational Use Only and Shall Not Be Used for Interpretive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Index to USP 39–NF 34 the Following Index Is for Convenience and Informational Use Only and Shall Not Be Used for Interpretive Index to USP 39–NF 34 The following Index is for convenience and informational use only and shall not be used for interpretive purposes. In addition to official articles, this Index may also include items recently omitted from the USP–NF in the indicated Book or Supplement. The requirements stated in the General Notices and Requirements section of the USP–NF apply to all articles recognized in the USP–NF and to all general chapters unless specifically stated otherwise. Although this revision (USP 39–NF 34) is generally official beginning May 1, 2016; particular provisions may indicate another earlier or later official date. In addition, the monographs and general chapters listed in this Index may reference other general chapter specifications. The articles listed in this Index are not intended to be autonomous standards and should only be interpreted in the context of the entire USP–NF publication. For the most current version of the USP–NF please see the USP–NF Online Combined Index to USP 39 and NF 34 Abaca-Acety I-1 Combined Index to USP 39 and NF 34, Volumes 1±4 Page citations refer to the pages of Volumes 1, 2, 3, and 4 of USP 39±NF 34. This index is repeated in its entirety in each volume. 1±2280 Volume 1 2281±4454 Volume 2 4455±6446 Volume 3 6447±7608 Volume 4 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, and tramadol hydrochloride tablets, 2323, A dextromethorphan, and 2323 pseudoephedrine, oral powder Acetanilide, 2084 Abacavir containing at least three of the Acetate oral solution, 2281 following, 2306 methyl, 2126 sulfate, 2283 and (salts of) chlorpheniramine, Acetate buffer, 2166 tablets, 2282 dextromethorphan, and TS, 2167 Abiraterone pseudoephedrine, oral solution Acetazolamide, 2325 acetate, 2285 containing at least three of the for injection, 2325 acetate tablets, 2286 following, 2308 oral suspension, 2326 Absolute and (salts of) chlorpheniramine, tablets, 2327 alcohol, 2085 dextromethorphan, and Acetic acid, 2084, 7139 ether, 2084 pseudoephedrine, tablets containing at ammonium acetate buffer TS, 2167 Absorbable least three of the following, 2310 diluted, 2084, 7139 dusting powder, 3640 chlorpheniramine maleate, and double-normal (2 N), 2177 gelatin film, 4096 dextromethorphan hydrobromide glacial, 2084, 2327 gelatin sponge, 4096 tablets, 2312 glacial, TS, 2167 surgical suture, 5978 and codeine phosphate capsules, 2314 and hydrocortisone otic solution, 4223 Absorbent and codeine phosphate oral solution, 2315 irrigation, 2328 cotton, 2084 and codeine phosphate oral suspension, metaphosphoric, TS, 2172 gauze, 4094 2316 otic solution, 2328 odorless paper, 2131 and codeine phosphate tablets, 2317 strong, TS, 2167 Acacia, 7137 dextromethorphan hydrobromide, Acetic acid in peptides, 357 syrup, 7137 doxylamine succinate, and Acetic anhydride, 2084 Acarbose, 2288 pseudoephedrine hydrochloride oral Acetohexamide, 2329 Acebutolol hydrochloride, 2289 solution, 2318 tablets, 2329 capsules, 2291 and diphenhydramine citrate tablets, 2319 Acetohydroxamic acid, 2329 Acepromazine maleate, 2292 diphenhydramine hydrochloride, and tablets, 2330 injection, 2293 pseudoephedrine hydrochloride tablets, Acetone, 2084, 7140 tablets, 2293 2320 anhydrous, 2084 Acesulfame potassium, 7138 and hydrocodone bitartrate tablets, 4214 neutralized, 2084, 2167 Acetal, 2084 isometheptene mucate, and Acetonitrile, 2084 Acetaldehyde, 2084 dichloralphenazone capsules, 4407 spectrophotometric, 2084 TS, 2167 and oxycodone capsules, 5225 Acetophenone, 2084 Acetaminophen, 2294 and oxycodone tablets, 5227 p-Acetotoluidide, 2084 aspirin and caffeine tablets, 2302 and pentazocine tablets, 5326 Acetylacetone, 2084 and aspirin tablets, 2301 and propoxyphene hydrochloride tablets, Acetyl chloride, 2084 butalbital and caffeine capsules, 2827 5582 Acetylcholine chloride, 2084, 2331 butalbital and caffeine tablets, 2828 and propoxyphene napsylate tablets, 5587 for ophthalmic solution, 2332 and caffeine tablets, 2303 and pseudoephedrine hydrochloride Acetylcysteine, 2333 capsules, 2296 tablets, 2322 and isoproterenol hydrochloride inhalation Index and (salts of) chlorpheniramine, oral solution, 2296 solution, 2334 dextromethorphan, and for effervescent oral solution, 2297 solution, 2334 pseudoephedrine, capsules containing at suppositories, 2298 N-Acetylglucosamine, 6447 least three of the following, 2304 oral suspension, 2298 3-Acetylthio-2-methylpropanoic acid, 2085 tablets, 2299 Acetyltributyl citrate, 7141 extended-release tablets, 2300 and tramadol hydrochloride oral suspension, 6214 I-2 Acety-Alumi Combined Index to USP 39 and NF 34 Acetyltriethyl citrate, 7141 Metaproterenol sulfate inhalation, 4757 Alginic acid, 7148 N-Acetyltyrosine, 6448 Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 2086 N-Acetyl-L-tyrosine ethyl ester, 2085 topical, 5446 Alkaline Acid Povidone±iodine topical, 5483 borate buffer, 2166 acrylic, 2085 Terbutaline sulfate inhalation, 6055 cupric citrate TS, 2167 alpha lipoic, 6731 Thimerosal topical, 6116 cupric citrate TS 2, 2167 dehydroacetic, 7272 Tolnaftate topical, 6194 cupric iodide TS, 2167 ferric chloride TS, 2167 Triamcinolone acetonide topical, 6237 cupric tartrate TS, 2167 ferrous sulfate TS, 2167 mercuric-potassium iodide TS, 2167 iminodiacetic, 2121 phosphatase enzyme, 2086 phthalate buffer, 2165 picrate TS, 2167 stannous chloride TS, 2167 Agar, 2085, 7143 pyrogallol TS, 2174 stannous chloride TS, stronger, 2167 Agarose, 2085 sodium hydrosulfite TS, 2167 Acid-neutralizing capacity 〈301〉, 287 Air, medical, 2348 Alkyl (C12-15) benzoate, 7149 Acidulated phosphate and sodium fluoride Air-helium certified standard, 2085 Alkylphenoxypolyethoxyethanol, 2086 topical solution, 5874 Alanine, 2349 Allantoin, 2377 Acitretin, 2335 L-Alanyl-L-glutamine, 6450 Allopurinol, 2378 capsules, 2336 Albendazole, 2350 oral suspension, 2380 Acoustic emission 〈1005〉, 763 oral suspension, 2351 tablets, 2380 Acrylic acid, 2085 tablets, 2351 Allyl isothiocyanate, 2381 Activated Albumen TS, 2167 Almond oil, 7149 alumina, 2085 Albumin Almotriptan charcoal, 2085, 3080 bovine serum, 2085 tablets, 2384 magnesium silicate, 2085 human, 2352 Almotriptan malate, 2381 Acyclovir, 2338 rAlbumin human, 7144 Aloe, 2385 capsules, 2339 Albuterol, 2353 Alpha for injection, 2340 sulfate, 2357 lipoic acid, 6731 ointment, 2341 tablets, 2353 Alpha-chymotrypsin, 2086 oral suspension, 2342 extended-release tablets, 2354 Alpha cyclodextrin hydrate, 2086 tablets, 2342 Alclometasone dipropionate, 2358 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Adamantane, 2085 cream, 2359 2086 Adapalene, 2343 ointment, 2360 Alphanaphthol, 2086 Ademetionine disulfate tosylate, 6449 Alcohol, 2085, 2361 Alphazurine 2G, 2162 Adenine, 2346 70 percent, 80 percent, and 90 percent, Alprazolam, 2386 sulfate, 2085 2085 oral suspension, 2387 Adenosine, 2347 absolute, 2085 tablets, 2388 injection, 2348 aldehyde-free, 2085 extended-release tablets, 2389 Adipic acid, 2085, 7142 alpha-(2-(methylamino)ethyl)benzyl, 2086 orally disintegrating tablets, 2393 Admissions amyl, 2085 Alprenolol hydrochloride, 2086 to NF 34, 7125 tert-amyl, 2089 Alprostadil, 2395 to USP 39, xxxv butyl, 7186 injection, 2397 Advisory Groups, xx dehydrated, 2085, 2363 Alteplase, 2398 Aerosol dehydrated isopropyl, 2085 for injection, 2401 Fluticasone propionate and salmeterol, denaturated, 2085 Alternative microbiological sampling methods inhalation, 4015 denaturated, TS, 2170 for nonsterile inhaled and nasal products determination 〈611〉, 454 〈610〉, 452 in dextrose injection, 2365 Altretamine, 2403 diluted, 2086, 7146 capsules, 2404 injection, dehydrated, 2364 Alum, 2086 Aerosol isobutyl, 2086 ammonium, 2086, 2405 Bacitracin and polymyxin B sulfate topical, isopropyl, 2086 potassium, 2137, 2405 2673 methyl, 2086 Alumina, 2086 Benzocaine, butamben, and tetracaine neutralized, 2086 activated, 2086 hydrochloride topical, 2713 phenol TS, 2167 anhydrous, 2086 Benzocaine and menthol topical, 2716 n-propyl, 2086 aspirin, codeine phosphate, and magnesia Benzocaine topical, 2704 rubbing, 2366 tablets, 2616 Betamethasone dipropionate topical, 2740 secondary butyl, 2086 aspirin, and magnesia tablets, 2610 Dexamethasone sodium phosphate tertiary butyl, 2086 aspirin, and magnesium oxide tablets, inhalation, 3407 Alcoholic 2611 Dexamethasone topical, 3398 ammonia TS, 2167 magnesia, and calcium carbonate Epinephrine bitartrate inhalation, 3715 mercuric bromide TS, 2167 chewable tablets, 2409 Epinephrine inhalation, 3712 potassium hydroxide TS, 2167 magnesia, calcium carbonate, and Ergotamine tartrate inhalation, 3736 potassium hydroxide TS 2, 2174 simethicone chewable tablets, 2410 Fluticasone propionate inhalation, 4001 TS, 2167 magnesia, and calcium carbonate oral Inhalation and nasal drug products: Alcoholometric table, 2274 suspension, 2408 aerosols, sprays, and Aldehyde dehydrogenase, 2086 magnesia, and simethicone oral powders±performance quality tests Alendronate sodium, 2367 suspension, 2412 〈601〉, 423 tablets, 2368 magnesia, and simethicone chewable Isoetharine mesylate inhalation, 4401 Alfadex, 7147 tablets, 2414 Isoproterenol hydrochloride inhalation, Alfentanil and magnesia oral suspension, 2406 Index 4415 hydrochloride, 2370 and magnesia tablets, 2407 Isoproterenol hydrochloride and injection, 2370 magnesium carbonate, and magnesium phenylephrine bitartrate inhalation, 4417 Alfuzosin hydrochloride, 2371 oxide tablets, 2417 Isoproterenol sulfate inhalation, 4420 extended-release tablets, 2372 and magnesium carbonate oral suspension, Lidocaine
Load more

Recommended publications
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al
    US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012.
    [Show full text]
  • Early Protective Effects of Tiotropium Bromide in Patients with Airways Hyperres P O N S I V E N E S S
    European Review for Medical and Pharmacological Sciences 2004; 8: 259-264 Early protective effects of tiotropium bromide in patients with airways hyperres p o n s i v e n e s s C. TERZANO, A. PETROIANNI, A. RICCI, L. D’ANTONI, L. ALLEGRA* Department of Cardiovascular and Respiratory Sciences, Respiratory Diseases Unit, Fondazione E. Lorillard Spencer Cenci, “La Sapienza” University - Rome (Italy) *Institute of Respiratory Diseases, University of Milan, Ospedale Maggiore IRCCS – Milan (Italy) Abstract. – Tiotropium is an anticholiner- Introduction gic drug for Ch ronic Obstructive Pulmonary Di sease (COPD) patients, with a peak b ron- Ti o t rop ium is a qu atern a ry amm o niu m chodilator effect observed after 1.5 to 2 hours and a long duration of action. The aim of our co ngener of atropine. It has been developed study was to quantify the early protection of a as a lon g-acting an ticho linergic bro n c h o d i l a- single dose of inhaled tiotropium against metha- tor for inhalation by patients with chronic ob- choline-induced bronchoconstriction in asthmat- s t ructive pu lmon ary d isease (COPD). Dru g ic patients with airway hyperresponsiveness. p ro p e rties o f ant icho lin ergic agent s have Ten subjects (7M, 3F), with history of asthma been well-kno wn to man y cultures for many and a baseline FEV (Forced Expiratory Volume 1 1 1 c e n t u r i e s . In the 1920s the d iscovery o f the sec) >80% of pred icted, were enrolled in the s t u d y.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Effect of Aminophylline on Diaphragmatic Contractility in the Piglet
    003 1-3998/90/2803-0196$02.00/0 PEDIATRIC RESEARCH Vol. 28, No. 3, 1990 Copyright 0 1990 International Pediatric Research Foundation, Inc. Printed in (I.S.A. Effect of Aminophylline on Diaphragmatic Contractility in the Piglet DENNIS E. MAYOCK, THOMAS A. STANDAERT, JON F. WATCHKO, AND DAVID E. WOODRUM1 University of Washington School of Medicine, Department of Pediatrics, Division of Neonatal and Respiratory Diseases, Seattle, Washington 98195 ABSTRACT. Minute ventilation, arterial blood gases, ar- of arterial oxygen > 8 kPa (60 torr) in room air, and a partial terial pH, cardiac output, and transdiaphragmatic force pressure of the arterial carbon dioxide 5 6.7 kPa (50 torr) were generation, both during spontaneous ventilation and in accepted for study. The animals were anesthetized with an i.v. response to phrenic nerve stiwulation during airway occlu- combination of chloralose (30 mg/kg) and urethane (1 50 mg/ sion at end expiration, were measured in nine anesthetized, kg) and studied in the supine position. Subsequent infusions of tracheostomized piglets before and 30 min after parenteral anesthetic were used if the piglet developed jaw clonus. A trache- infusion of 20 mg/kg aminophylline. Serum theophylline ostomy was placed and connected to a two-way nonrebreathing levels averaged 109 f 21 ~mol/L(19.7 f 3.7 ~g/mL)at valve (model 2384, Hans Rudolph, Inc., Kansas City, MO). 30 min postinfusion. No significant changes were noted in Inspiratory flow was detected by a hot-wire anemometer and pH, blood gases, blood Pressure, or ventilatory measures integrated to provide tidal volume. All animals breathed 50% after aminophylline.
    [Show full text]
  • Excluded Drug List
    Excluded Drug List The following drugs are excluded from coverage as they are not approved by the FDA ACTIVE-PREP KIT I (FLURBIPROFEN-CYCLOBENZAPRINE CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT II (KETOPROFEN-BACLOFEN-GABAPENTIN CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT III (KETOPROFEN-LIDOCAINE-GABAPENTIN CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT IV (TRAMADOL-GABAPENTIN-MENTHOL-CAMPHOR CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT V (ITRACONAZOLE-PHENYTOIN SODIUM CREAM CMPD KIT) ­ ADAZIN CREAM (BENZO-CAPSAICIN-LIDO-METHYL SALICYLATE CRE) ­ AFLEXERYL-LC PAD (LIDOCAINE-MENTHOL PATCH) ­ AFLEXERYL-MC PAD (CAPSAICIN-MENTHOL TOPICAL PATCH) ­ AIF #2 DRUG PREPERATION KIT (FLURBIPROFEN-GABAPENT-CYCLOBEN-LIDO-DEXAMETH CREAM COMPOUND KIT) ­ AGONEAZE (LIDOCAINE-PRILOCAINE KIT) ­ ALCORTIN A (IODOQUINOL-HYDROCORTISONE-ALOE POLYSACCHARIDE GEL) ­ ALEGENIX MIS (CAPSAICIN-MENTHOL DISK) ­ ALIVIO PAD (CAPSAICIN-MENTHOL PATCH) ­ ALODOX CONVENIENCE KIT (DOXYCYCLINE HYCLATE TAB 20 MG W/ EYELID CLEANSERS KIT) ­ ANACAINE OINT (BENZOCAINE OINT) ­ ANODYNZ MIS (CAPSAICIN-MENTHOL DISK) ­ APPFORMIN/D (METFORMIN & DIETARY MANAGEMENT CAP PACK) ­ AQUORAL (ARTIFICIAL SALIVA - AERO SOLN) ­ ATENDIA PAD (LIDOCAINE-MENTHOL PATCH) ­ ATOPICLAIR CRE (DERMATOLOGICAL PRODUCTS MISC – CREAM) ­ Page 1 of 9 Updated JANUARY 2017 Excluded Drug List AURSTAT GEL/CRE (DERMATOLOGICAL PRODUCTS MISC) ­ AVALIN-RX PAD (LIDOCAINE-MENTHOL PATCH) ­ AVENOVA SPRAY (EYELID CLEANSER-LIQUID) ­ BENSAL HP (SALICYLIC ACID & BENZOIC ACID OINT) ­ CAMPHOMEX SPRAY (CAMPHOR-HISTAMINE-MENTHOL LIQD SPRAY) ­ CAPSIDERM PAD (CAPSAICIN-MENTHOL
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET Revision Date 13-Dec-2020 Revision Number 6 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier Product Description: Neopentyl alcohol Cat No. : 128250000; 128250100; 128250500 Synonyms 2,2-Dimethyl-1-propanol CAS-No 75-84-3 EC-No. 200-907-3 Molecular Formula C5 H12 O 1.2. Relevant identified uses of the substance or mixture and uses advised against Recommended Use Laboratory chemicals. Uses advised against No Information available 1.3. Details of the supplier of the safety data sheet Company UK entity/business name Fisher Scientific UK Bishop Meadow Road, Loughborough, Leicestershire LE11 5RG, United Kingdom EU entity/business name Acros Organics BVBA Janssen Pharmaceuticalaan 3a 2440 Geel, Belgium E-mail address [email protected] 1.4. Emergency telephone number For information US call: 001-800-ACROS-01 / Europe call: +32 14 57 52 11 Emergency Number US:001-201-796-7100 / Europe: +32 14 57 52 99 CHEMTREC Tel. No.US:001-800-424-9300 / Europe:001-703-527-3887 SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the substance or mixture CLP Classification - Regulation (EC) No 1272/2008 Physical hazards Flammable solids Category 2 (H228) Health hazards ______________________________________________________________________________________________ ACR12825 Page 1 / 10 SAFETY DATA SHEET Neopentyl alcohol Revision Date 13-Dec-2020 ______________________________________________________________________________________________ Acute Inhalation Toxicity - Dusts and Mists (H332) Category 4 Specific target organ toxicity - (single exposure) (H335) Category 3 (H336) Environmental hazards Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16 2.2.
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes Against Salivary SARS-Cov-2
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2. Rola Elzein1*, Fadi Abdel-Sater2*, Soha Fakhreddine3, Pierre Abi Hanna3, Rita Feghali4, Hassan Hamad5, Fouad Ayoub6 ¹Department of Pediatric Dentistry and Public Dental Health, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon 2Laboratory of Cancer Biology and Cellular Immunology, Department of Biological Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon 3Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon 4Department of Laboratory Medicine, Rafik Hariri University Hospital, Beirut, Lebanon 5Medical care Laboratory, Faculty of Public Health IV, Lebanese University, Zahle, Lebanon 6Department of Forensic Odontology, Human Identification and Anthropology, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon *CORRESPONDING AUTHORS: Rola ELZEIN; Mobile number: 009613252480; Email address: [email protected] Fadi Abdelsater; Mobile number: 009613781176; Email address: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]